Exome sequencing and characterization of 49,960 individuals in the UK Biobank

Cristopher V. Van Hout(Regeneron (United States)), Ioanna Tachmazidou(AstraZeneca (United Kingdom)), Joshua Backman(Regeneron (United States)), Joshua Hoffman(GlaxoSmithKline (United States)), Daren Liu(Regeneron (United States)), Ashutosh Kumar Pandey(GlaxoSmithKline (United States)), Claudia Gonzaga‐Jauregui(Regeneron (United States)), Shareef Khalid(Regeneron (United States)), Bin Ye(Regeneron (United States)), Nilanjana Banerjee(Regeneron (United States)), Alexander Li(Regeneron (United States)), Colm O’Dushlaine(Regeneron (United States)), Anthony Marcketta(Regeneron (United States)), Jeffrey Staples(Regeneron (United States)), Claudia Schurmann(Hasso Plattner Institute), Alicia Hawes(Regeneron (United States)), Evan K. Maxwell(Regeneron (United States)), Leland Barnard(Regeneron (United States)), Alexander Lopez(Regeneron (United States)), John S. Penn(Regeneron (United States)), Lukas Habegger(Regeneron (United States)), Andrew Blumenfeld(Regeneron (United States)), Xiaodong Bai(Regeneron (United States)), Sean O’Keeffe(Regeneron (United States)), Ashish Yadav(Regeneron (United States)), Kavita Praveen(Regeneron (United States)), Marcus B. Jones(Regeneron (United States)), William Salerno(Regeneron (United States)), Wendy K. Chung(Columbia University Irving Medical Center), Ida Surakka(University of Michigan), Cristen J. Willer(University of Michigan), Kristian Hveem(Norwegian University of Science and Technology), Joseph B. Leader(Geisinger Medical Center), David J. Carey(Geisinger Medical Center), David H. Ledbetter(Geisinger Medical Center), Lon R. Cardon(GlaxoSmithKline (United Kingdom)), George D. Yancopoulos(Regeneron (United States)), Aris N. Economides(Regeneron (United States)), Giovanni Coppola(Regeneron (United States)), Alan R. Shuldiner(Regeneron (United States)), Suganthi Balasubramanian(Regeneron (United States)), Michael Cantor(Regeneron (United States)), Matthew R. Nelson(Deerfield (United States)), John C. Whittaker(GlaxoSmithKline (United Kingdom)), Jeffrey G. Reid(Regeneron (United States)), Jonathan Marchini(Regeneron (United States)), John D. Overton(Regeneron (United States)), Robert A. Scott(GlaxoSmithKline (United Kingdom)), Gonçalo R. Abecasis(Regeneron (United States)), Laura M. Yerges-Armstrong(GlaxoSmithKline (United States)), Aris Baras(Regeneron (United States))
Nature
October 21, 2020
Cited by 629Open Access
Full Text

Abstract

. Here we describe the release of exome-sequence data for the first 49,960 study participants, revealing approximately 4 million coding variants (of which around 98.6% have a frequency of less than 1%). The data include 198,269 autosomal predicted loss-of-function (LOF) variants, a more than 14-fold increase compared to the imputed sequence. Nearly all genes (more than 97%) had at least one carrier with a LOF variant, and most genes (more than 69%) had at least ten carriers with a LOF variant. We illustrate the power of characterizing LOF variants in this population through association analyses across 1,730 phenotypes. In addition to replicating established associations, we found novel LOF variants with large effects on disease traits, including PIEZO1 on varicose veins, COL6A1 on corneal resistance, MEPE on bone density, and IQGAP2 and GMPR on blood cell traits. We further demonstrate the value of exome sequencing by surveying the prevalence of pathogenic variants of clinical importance, and show that 2% of this population has a medically actionable variant. Furthermore, we characterize the penetrance of cancer in carriers of pathogenic BRCA1 and BRCA2 variants. Exome sequences from the first 49,960 participants highlight the promise of genome sequencing in large population-based studies and are now accessible to the scientific community.


Related Papers

No related papers found

Powered by citation graph analysis